ProQR Therapeutics NV (PRQR) Given Outperform Rating at Leerink Swann
A number of other equities research analysts have also recently weighed in on PRQR. Zacks Investment Research upgraded shares of ProQR Therapeutics NV from a sell rating to a hold rating in a research report on Friday, September 23rd. Chardan Capital assumed coverage on shares of ProQR Therapeutics NV in a report on Monday, June 20th. They issued a neutral rating and a $4.50 price objective for the company. Janney Montgomery Scott assumed coverage on shares of ProQR Therapeutics NV in a report on Wednesday, September 28th. They issued a neutral rating and a $7.00 price objective for the company. Finally, JMP Securities restated a buy rating on shares of ProQR Therapeutics NV in a report on Tuesday, September 6th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of $14.15.
Shares of ProQR Therapeutics NV (NASDAQ:PRQR) traded down 1.88% on Friday, reaching $6.25. The company had a trading volume of 5,934 shares. ProQR Therapeutics NV has a 12 month low of $3.48 and a 12 month high of $16.23. The stock’s market cap is $145.91 million. The stock has a 50-day moving average price of $6.42 and a 200-day moving average price of $5.41.
ProQR Therapeutics NV (NASDAQ:PRQR) last announced its quarterly earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by $0.00. Analysts predict that ProQR Therapeutics NV will post ($2.09) earnings per share for the current fiscal year.
An institutional investor recently raised its position in ProQR Therapeutics NV stock. Redmile Group LLC raised its position in shares of ProQR Therapeutics NV (NASDAQ:PRQR) by 5.2% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 581,638 shares of the biopharmaceutical company’s stock after buying an additional 28,925 shares during the period. Redmile Group LLC owned about 2.49% of ProQR Therapeutics NV worth $2,815,000 at the end of the most recent quarter. 39.21% of the stock is currently owned by hedge funds and other institutional investors.
About ProQR Therapeutics NV
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
Receive News & Stock Ratings for ProQR Therapeutics NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics NV and related stocks with our FREE daily email newsletter.